Penn’s Breast and Ovarian Cancer Risk Evaluation Program is distinguished in a number of ways, including:
Penn’s program is led by one of the foremost authorities in breast cancer genetics, Susan Domchek, MD.
Penn’s service is backed by one of the largest breast cancer research programs in the country.
Penn scientists have contributed to new standards in treatment and risk prevention, including a landmark study that showed that bilateral prophylactic oophorectomy (BPO) reduces risk of ovarian cancer when the surgery is performed prior to menopause.
In recognition of its expertise, the National Cancer Institute has selected the Abramson Cancer Center as one of eight institutions for the Cancer Genetics Network. This select group of cancer centers work together to conduct cancer genetics research.